Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 2 |
2022 | 5 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned.
Curr Oncol. 2022 Aug 7;29(8):5616-5626. doi: 10.3390/curroncol29080443.
Curr Oncol. 2022.
PMID: 36005181
Free PMC article.
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V, Luo J, Parmar A, Dai WF, Beca JM, Raphael MJ, Isaranuwatchai W, Habbous S, Tadrous M, Earle CC, Biagi JJ, Mittmann N, Arias J, Gavura S, Chan KKW.
Arciero V, et al.
JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac047. doi: 10.1093/jncics/pkac047.
JNCI Cancer Spectr. 2022.
PMID: 35758620
Free PMC article.
Item in Clipboard
Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
Dai WF, de Oliveira C, Blommaert S, Pataky RE, Tran D, Aurangzeb Z, Kendell C, Folkins C, Somayaji C, Dowden J, Cheung W, Strumpf E, Beca JM, McClure C, Urquhart R, McDonald JT, Alvi R, Turner D, Peacock S, Denburg A, Mercer RE, Muñoz C, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration.
Dai WF, et al.
Curr Oncol. 2022 Mar 17;29(3):2046-2063. doi: 10.3390/curroncol29030165.
Curr Oncol. 2022.
PMID: 35323365
Free PMC article.
Item in Clipboard
Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.
Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Mercer RE, Chan KKW.
Dai WF, et al.
JAMA Netw Open. 2022 Feb 1;5(2):e2145460. doi: 10.1001/jamanetworkopen.2021.45460.
JAMA Netw Open. 2022.
PMID: 35226087
Free PMC article.
Item in Clipboard
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Chan KKW.
Dai WF, et al.
JAMA Oncol. 2022 Apr 1;8(4):597-606. doi: 10.1001/jamaoncol.2021.8049.
JAMA Oncol. 2022.
PMID: 35201264
Free PMC article.
Item in Clipboard
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
Dai WF, Craig E, Fraser B, Chambers A, Mai H, Brown MB, Earle CC, Evans WK, Geirnaert M, Taylor M, Trudeau M, Sperber D, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration.
Dai WF, et al.
Curr Oncol. 2021 Nov 12;28(6):4645-4654. doi: 10.3390/curroncol28060392.
Curr Oncol. 2021.
PMID: 34898572
Free PMC article.
Item in Clipboard
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B, Lungu E, Mitera G, Potashnik T, Reiman A, Ritcher T, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group.
Dai WF, et al.
Curr Oncol. 2021 Oct 16;28(5):4174-4183. doi: 10.3390/curroncol28050354.
Curr Oncol. 2021.
PMID: 34677272
Free PMC article.
Item in Clipboard
Cite
Cite